Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer

Cited by (1,000)

Items 101–200 of 1,000

1. CompoundEGFRmutation is frequently detected with co-mutations of actionable genes and associated with poor clinical outcome in lung adenocarcinoma
   Eun Young Kim, Eun Na Cho, Heae Surng Park, Ji Young Hong, Seri Lim, Jong Pil Youn, Seung Yong Hwang, Yoon Soo Chang · 2016 · Cancer Biology & Therapy
2. Comparison of Reverse Transcription-Polymerase Chain Reaction, Immunohistochemistry, and Fluorescence In Situ Hybridization Methodologies for Detection of Echinoderm Microtubule-Associated Proteinlike 4–Anaplastic Lymphoma Kinase Fusion–Positive Non–Small Cell Lung Carcinoma: Implications for Optimal Clinical Testing
   Michelle L. Wallander, Katherine B. Geiersbach, Sheryl R. Tripp, Lester James Layfield · 2012 · Archives of Pathology & Laboratory Medicine
3. TRAF4 Is a Critical Molecule for Akt Activation in Lung Cancer
   Wei Li, Cong Peng, Mee‐Hyun Lee, DoYoung Lim, Feng Zhu, Yang Fu, Ge Yang, Yuqiao Sheng, Lanbo Xiao, Xin Dong et al. · 2013 · Cancer Research
4. Preclinical Rationale for PI3K/Akt/mTOR Pathway Inhibitors as Therapy for Epidermal Growth Factor Receptor Inhibitor-Resistant Non–Small-Cell Lung Cancer
   Shirish M. Gadgeel, Antoinette J. Wozniak · 2013 · Clinical Lung Cancer
5. Reprogramming Tumor-Associated Macrophages To Reverse EGFRT790M Resistance by Dual-Targeting Codelivery of Gefitinib/Vorinostat
   Huige Peng, Binfan Chen, Wei Huang, Yubo Tang, Yifan Jiang, Wenyuan Zhang, Yongzhuo Huang · 2017 · Nano Letters
6. Role and regulation of coordinately expressedde novopurine biosynthetic enzymesPPATandPAICSin lung cancer
   Moloy T. Goswami, Guoan Chen, Balabhadrapatruni V. S. K. Chakravarthi, Satya S. Pathi, Sharath Kumar Anand, Shannon L. Carskadon, Thomas J. Giordano, Arul M. Chinnaiyan, Dafydd G. Thomas, Nallasivam Palanisamy et al. · 2015 · Oncotarget
7. Bax/Bcl-2 Cascade Is Regulated by the EGFR Pathway: Therapeutic Targeting of Non-Small Cell Lung Cancer
   Manzar Alam, Shoaib Alam, Anas Shamsi, Mohd Adnan, Abdelbaset Mohamed Elasbali, Waleed Abu Al‐Soud, Mousa M. Alreshidi, Yousef MohammedRabaa Hawsawi, Anitha Tippana, Visweswara Rao Pasupuleti et al. · 2022 · Frontiers in Oncology
8. Uncommon Epidermal Growth Factor Receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance
   Massarelli, Erminia, Johnson, Faye M., Erickson, Heidi S., Wistuba, Ignacio I., Papadimitrakopoulou, Vassiliki · 2013 · Lung Cancer
9. The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma
   Xuejiao Liu, Xiangyu Chen, Lin Shi, Qianqian Shan, Qiyu Cao, Chenglong Yue, Huan Li, Shengsheng Li, Jie Wang, Shangfeng Gao et al. · 2019 · Journal of Experimental & Clinical Cancer Research
10. EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function
    Janyaporn Phuchareon, Frank P. McCormick, David W. Eisele, Osamu Tetsu · 2015 · Proceedings of the National Academy of Sciences
11. Nuclear factor of activated T cells in cancer development and treatment
    Jiawei Shou, Jing Jing, Jiansheng Xie, Liangkun You, Jing Zhao, Junlin Yao, Weidong Han, Hongming Pan · 2015 · Cancer Letters
12. The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers
    Adam J. Atherly, D. Ross Camidge · 2012 · British Journal of Cancer
13. Combination Strategies Using EGFR-TKi in NSCLC Therapy: Learning from the Gap between Pre-Clinical Results and Clinical Outcomes
    Zheng Yang, Kin Yip Tam · 2018 · International Journal of Biological Sciences
14. Fractional proliferation: a method to deconvolve cell population dynamics from single-cell data
    Darren R. Tyson, Shawn P. Garbett, Peter L. Frick, Vito Quaranta · 2012 · Nature Methods
15. Emerging evidence and treatment paradigm of non-small cell lung cancer
    Si‐Yang Maggie Liu, Mei-Mei Zheng, Yi Pan, Si‐Yang Maggie Liu, Yangqiu Li, Yi-Long Lung Cancer Wu · 2023 · Journal of Hematology & Oncology
16. High performance of targeted next generation sequencing on variance detection in clinical tumor specimens in comparison with current conventional methods
    Dan Su, Dadong Zhang, Kaiyan Chen, Jing Nan Lu, Junzhou Wu, Xinkai Cao, Lisha Ying, Qihuang Jin, Yizhou Ye, Zhenghua Xie et al. · 2017 · Journal of Experimental & Clinical Cancer Research
17. Local phosphocycling mediated by LOK/SLK restricts ezrin function to the apical aspect of epithelial cells
    Raghuvir Viswanatha, Patrice Y. Ohouo, Marcus Bustamante Smolka, Anthony P. Bretscher · 2012 · The Journal of Cell Biology
18. The Genomics of Lung Adenocarcinoma: Opportunities for Targeted Therapies
    Heidi E. Greulich · 2010 · Genes & Cancer
19. Lymphatic vessel: Origin, heterogeneity, biological functions and therapeutic targets
    Zhaoliang Hu, Xushi Zhao, Zhonghua Wu, Bicheng Qu, Minxian Yuan, Yanan Xing, Yongxi Song, Zhenning Wang · 2024 · Signal Transduction and Targeted Therapy
20. Afatinib—new therapy option for EGFR-mutant lung cancer
    Yu, Helena A., Pao, William · 2013 · Nature Reviews Clinical Oncology
21. Cyclin-dependent kinase 2 is an ideal target for ovary tumors with elevated cyclin E1 expression
    Liu Yang, Dongdong Fang, Huijun Chen, Yi-Yu Lu, Zheng Dong, Han‐Fei Ding, Qing Jing, Shibing Su, Shuang Huang · 2015 · Oncotarget
22. Resveratrol inhibits Hexokinases II mediated glycolysis in non-small cell lung cancer via targeting Akt signaling pathway
    Wěi Li, Xiaoqian Ma, Na Li, Huasheng Liu, Qiong Dong, Juan Zhang, Cejun Yang, Yin Liu, Qi Liang, Shengwang Zhang et al. · 2016 · Experimental Cell Research
23. Evidence of Clinical Utility: An Unmet Need in Molecular Diagnostics for Patients with Cancer
    David R. Parkinson, Robert Thomas Mccormack, Susan M. Keating, Steven I. Gutman, Stanley R. Hamilton, Elizabeth A. Mansfield, Margaret Piper, Patricia A. Deverka, Felix W. Frueh, John Milburn Jessup et al. · 2014 · Clinical Cancer Research
24. Escaping ALK Inhibition: Mechanisms of and Strategies to Overcome Resistance
    Christine Marie Lovly, William J. Pao · 2012 · Science Translational Medicine
25. Lung cancer tumorigenicity and drug resistance are maintained through ALDHhiCD44hi tumor initiating cells
    Jing Liu, Zhijie Xiao, Sunny Kit‐Man Wong, Vicky Pui‐Chi Tin, Ka-Yan Ho, Junwen Wang, Mai Har Sham, Maria Pik Wong · 2013 · Oncotarget
26. Liquid Biopsy in Lung Cancer: Clinical Applications of Circulating Biomarkers (CTCs and ctDNA)
    Minji Lim, Chi‐Ju Kim, Vijaya Sunkara, Mi‐Hyun Kim, Yoon‐Kyoung Cho · 2018 · Micromachines
27. Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives
    Miriam Grazia Ferrara, Vincenzo Di Noia, Ettore D’Argento, Emanuele Vita, Paola Damiano, Antonella Cannella, Marta Ribelli, Sara Pilotto, Michèle Milella, Giampaolo Tortora et al. · 2020 · Cancers
28. Enhanced dimerization drives ligand-independent activity of mutant epidermal growth factor receptor in lung cancer
    Christopher C. Valley, Donna J. Arndt‐Jovin, Narain Karedla, Mara P. Steinkamp, Alexey I. Chizhik, William S. Hlavacek, Bridget Smith Wilson, Keith A. Lidke, Diane S. Lidke · 2015 · Molecular Biology of the Cell
29. The Hedgehog Signaling Networks in Lung Cancer: The Mechanisms and Roles in Tumor Progression and Implications for Cancer Therapy
    Yoshinori Abe, Nobuyuki Tanaka · 2016 · BioMed Research International
30. Survival of lung adenocarcinoma patients with malignant pleural effusion
    Shang‐Gin Wu, Chong‐Jen Yu, Meng‐Feng Tsai, Wei‐Yu Liao, Chih-Hsin Yang, I‐Shiow Jan, Pan‐Chyr Yang, Jin‐Yuan Shih · 2012 · European Respiratory Journal
31. Mutational landscapes of tongue carcinoma reveal recurrent mutations in genes of therapeutic and prognostic relevance
    Andre Luiz Vettore, Kalpana Ramnarayanan, Gregory D. Poore, Kevin Junliang Lim, Choon Kiat Ong, Kie Kyon Huang, Hui Sun Leong, Fui Teen Chong, Tony Kiat‐Hon Lim, Weng Khong Lim et al. · 2015 · Genome Medicine
32. Repurposing sertraline sensitizes non–small cell lung cancer cells to erlotinib by inducing autophagy
    Xingwu Jiang, Weiqiang Lü, Xiaoyang Shen, Quan Wang, Jing Lv, Mingyao Liu, Feixiong Cheng, Zhongming Zhao, Xiufeng Pang · 2018 · JCI Insight
33. cAMP-dependent protein kinase is essential for hypoxia-mediated epithelial–mesenchymal transition, migration, and invasion in lung cancer cells
    Dooniya Shaikh, Qiyuan Zhou, Tianji Chen, Joyce Christina F. Ibe, J. Usha Raj, Guofei Zhou · 2012 · Cellular Signalling
34. Mitochondrial DNA mutations in respiratory complex‐I in never‐smoker lung cancer patients contribute to lung cancer progression and associated with EGFR gene mutation
    Santanu Dasgupta, Ethan Soudry, Nitai D. Mukhopadhyay, Chunbo Shao, John Yee, Stephan Lam, Wan L. Lam, Wei Yan Zhang, Adi F. Gazdar, Paul B. Fisher et al. · 2011 · Journal of Cellular Physiology
35. Magnetic particle targeting for diagnosis and therapy of lung cancers
    Mahsa Saadat, Mohammad K. D. Manshadi, Mehdi Mohammadi, Mohammad Javad Zare, Mohammad Zarei, Reza Kamali, Amir Sanati‐Nezhad · 2020 · Journal of Controlled Release
36. Oncogenes in non-small-cell lung cancer: emerging connections and novel therapeutic dynamics
    Giulia Maria Stella, Maurizio Luisetti, Ernesto Pozzi, Paolo Maria Comoglio · 2013 · The Lancet Respiratory Medicine
37. Drug Resistance to EGFR Inhibitors in Lung Cancer
    Osamu Tetsu, Matthew J. Hangauer, Janyaporn Phuchareon, David W. Eisele, Frank P. McCormick · 2016 · Chemotherapy
38. Translating genomic information into clinical medicine: Lung cancer as a paradigm
    Mia Alyce Levy, Christine Marie Lovly, William J. Pao · 2012 · Genome Research
39. L718Q mutant EGFR escapes covalent inhibition by stabilizing a non-reactive conformation of the lung cancer drug osimertinib
    Donatella Callegari, Kara E. Ranaghan, Christopher J. Woods, Roberta Minari, Marcello Tiseo, Marco Mor, Adrian John Mulholland, Alessio Lodola · 2018 · Chemical Science
40. Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies
    Leto, Simonetta M., Trusolino, Livio · 2014 · Journal of Molecular Medicine
41. Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells
    Christoph K. Weber, Thiemo B. Schreiber, Henrik Daub · 2011 · Journal of Proteomics
42. Epidermal Growth Factor Receptor: Pathway, Therapies, and Pipeline
    John R. Goffin, Kevin M. Zbuk · 2013 · Clinical Therapeutics
43. Modulating lysosomal function through lysosome membrane permeabilization or autophagy suppression restores sensitivity to cisplatin in refractory non-small-cell lung cancer cells
    Magdalena L. Circu, James A. Cardelli, Martin P. Barr, Kenneth John O'Byrne, Glenn Morris Mills, Hazem Edmond El-Osta · 2017 · PLoS ONE
44. EGFR Regulates the Development and Microarchitecture of Intratumoral Angiogenic Vasculature Capable of Sustaining Cancer Cell Intravasation
    Petra Minder, Ewa Zając, James P. Quigley, Elena I. Deryugina · 2015 · Neoplasia
45. Guideline on the requirements of external quality assessment programs in molecular pathology
    J. Han van Krieken, Nicola Normanno, Fiona Helen Blackhall, Elke Boone, Gerardo Botti, Fátima Carneiro, Ilhan Celik, Fortunato Ciardiello, Ian A. Cree, Zandra C. Deans et al. · 2012 · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
46. Yes and Lyn play a role in nuclear translocation of the Epidermal Growth Factor Receptor
    M. Iida, Toni M. Brand, D. Campbell, Chun-Rong Li, D. Wheeler · 2012 · Oncogene
47. Establishment of a human 3D lung cancer model based on a biological tissue matrix combined with a Boolean in silico model
    Anna T. Stratmann, David Fecher, Gaby Wangorsch, Claudia Göttlich, Thorsten Walles, Heike Walles, Thomas Dandekar, Gudrun Dandekar, Sarah Nietzer · 2013 · Molecular Oncology
48. Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in EGFR -Mutant Non–Small Cell Lung Cancer Cells
    Kei Namba, Kazuhiko Shien, Yuta Takahashi, Hidejiro Torigoe, Hiroki Sato, Takahiro Yoshioka, Tatsuaki Takeda, Eisuke Kurihara, Yusuke Ogoshi, Hiromasa Yamamoto et al. · 2018 · Molecular Cancer Research
49. Oncogenic RIT1 mutations in lung adenocarcinoma
    Berger Ah, Marcin B. Imielinski, Fujiko F. Duke, Jeremiah A. Wala, Nathan O. Kaplan, Shi Gx, Douglas Andres, Matthew M. Meyerson · 2014 · Oncogene
50. Trisubstituted Imidazoles with a Rigidized Hinge Binding Motif Act As Single Digit nM Inhibitors of Clinically Relevant EGFR L858R/T790M and L858R/T790M/C797S Mutants: An Example of Target Hopping
    Michael Juchum, Marcel Günther, Eva Döring, Adrian Sievers‐Engler, Michael Lämmerhofer, Stefan Laufer · 2017 · Journal of Medicinal Chemistry
51. DNA Methylation Profiling Defines Clinically Relevant Biological Subsets of Non–Small Cell Lung Cancer
    Walter Kim, Thomas Holcomb, Tom Januario, Pan Du, Marie Evangelista, Nithya Kartha, Leonardo A. Iniguez, Robert H. Soriano, Ling Y. Huw, Howard Marvin Stern et al. · 2012 · Clinical Cancer Research
52. HDAC Inhibitors: Dissecting Mechanisms of Action to Counter Tumor Heterogeneity
    Dimitris Karagiannis, Theodoros N Rampias · 2021 · Cancers
53. Insight into the Therapeutic Selectivity of the Irreversible EGFR Tyrosine Kinase Inhibitor Osimertinib through Enzyme Kinetic Studies
    Xiang Zhai, Richard A. Ward, Peter C. Doig, Argyrides Argyrou · 2020 · Biochemistry
54. Correlation of Activated STAT3 Expression with Clinicopathologic Features in Lung Adenocarcinoma and Squamous Cell Carcinoma
    Richeng Jiang, Ziliang Jin, Zhujun Liu, Leina Sun, Liuchun Wang, Kai Li · 2011 · Molecular Diagnosis & Therapy
55. lncRNA DLEU2 modulates cell proliferation and invasion of non-small cell lung cancer by regulating miR-30c-5p/SOX9 axis
    Yongchun Zhou, Hutao Shi, Yaqian Du, Guangqiang Zhao, Xiaoxiong Wang, Quan Li, Junxi Liu, Lianhua Ye, Zhenghai Shen, Yinjin Guo et al. · 2019 · Aging
56. Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in EGFR -Mutant Lung Cancer
    Takayuki Nakagawa, Shinji Takeuchi, Tadaaki Yamada, Shigeki Nanjo, Daisuke Ishikawa, Takako Sano, Kenji Kita, Takahiro Nakamura, Kunio Matsumoto, Kenichi Suda et al. · 2012 · Molecular Cancer Therapeutics
57. Pharmacogenomic biomarkers for personalized cancer treatment
    Cristina Rodríguez‐Antona, Miquel Tarón · 2014 · Journal of Internal Medicine
58. Evaluation of the Antitumor Effects and Mechanisms of PF00299804, a Pan-HER Inhibitor, Alone or in Combination with Chemotherapy or Targeted Agents in Gastric Cancer
    Hyun-Jin Nam, Keith A. Ching, Julie L.C. Kan, Hwang‐Phill Kim, Sae‐Won Han, Seock‐Ah Im, Tae‐You Kim, James G. Christensen, Do‐Youn Oh, Yung‐Jue Bang · 2011 · Molecular Cancer Therapeutics
59. The Use of Conformational Restriction in Medicinal Chemistry
    Pedro de Sena Murteira Pinheiro, Daniel Alencar Rodrigues, Rodolfo do Couto Maia, Sreekanth Thota, Carlos Alberto Manssour Fraga · 2019 · Current Topics in Medicinal Chemistry
60. The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells
    M. C. Chen, C. H. Chen, J-C Wang, A-C Tsai, J-P Liou, S-L Pan, C-M Teng · 2013 · Cell Death and Disease
61. CRISPR-Barcoding for Intratumor Genetic Heterogeneity Modeling and Functional Analysis of Oncogenic Driver Mutations
    Alexis A. Guernet, Sathish Kumar Mungamuri, Dorthe Cartier, Ravi Sachidanandam, Anitha Devi Jayaprakash, Sahil Adriouch, Myriam Vézain, Françoise Charbonnier, Guy Rohkin, Sophie Coutant et al. · 2016 · Molecular Cell
62. Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives
    Haiquan Chen, Xinghua Cheng · 2014 · OncoTargets and Therapy
63. PLGA Porous Microspheres Dry Powders for Codelivery of Afatinib‐Loaded Solid Lipid Nanoparticles and Paclitaxel: Novel Therapy for EGFR Tyrosine Kinase Inhibitors Resistant Nonsmall Cell Lung Cancer
    Yao Yang, Zhengwei Huang, Jinyuan Li, Ziran Mo, Ying Huang, Cheng Ma, Wenhao Wang, Xin Pan, Chuanbin Wu · 2019 · Advanced Healthcare Materials
64. Aptamer-Dendrimer Bioconjugates for Targeted Delivery of miR-34a Expressing Plasmid and Antitumor Effects in Non-Small Cell Lung Cancer Cells
    Hongmei Wang, Xin Zhao, Caihong Guo, Dunqiang Ren, Yandong Zhao, Wei Lie Xiao, Wenjie Jiao · 2015 · PLoS ONE
65. Activating ERBB4 mutations in non-small cell lung cancer
    Kari J. Kurppa, Konstantin A. Denessiouk, Mark S. Johnson, Klaus Elenius · 2015 · Oncogene
66. Aldehyde dehydrogenase is used by cancer cells for energy metabolism
    Joon Hee Kang, Seon-Hyeong Lee, Dongwan Hong, Jae‐Seon Lee, Hee‐Sung Ahn, Ju-Hyun Ahn, Tae Wha Seong, Chang Hun Lee, Hyonchol Jang, Kyeong Man Hong et al. · 2016 · Experimental & Molecular Medicine
67. Reciprocal positive regulation between Cx26 and PI3K/Akt pathway confers acquired gefitinib resistance in NSCLC cells via GJIC-independent induction of EMT
    Jie Yang, Gang Qin, M Luo, Jiangyuan Chen, Q Zhang, L Li, Ling Pan, Shanyu Qin · 2015 · Cell Death and Disease
68. Real-World Patterns of EGFR Testing and Treatment with Erlotinib for Non-Small Cell Lung Cancer in the United States
    Lindsey Enewold, Anish Thomas · 2016 · PLoS ONE
69. Rosemary extract reduces Akt/mTOR/p70S6K activation and inhibits proliferation and survival of A549 human lung cancer cells
    Jessy Moore, Mark Megaly, Adam J. MacNeil, Panagiota Klentrou, Evangelia Tsiani · 2016 · Biomedicine & Pharmacotherapy
70. Synthesis and anticancer activity evaluation of new 1,2,3-triazole-4-carboxamide derivatives
    Nazariy T. Pokhodylo, Olga Ya. Shyyka, V. S. Matiychuk · 2013 · Medicinal Chemistry Research
71. Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells
    Yongik Lee, Yian Wang, Michael A. James, Joseph H. Jeong, Ming You · 2015 · Molecular Carcinogenesis
72. Impact of Systematic EGFR and KRAS Mutation Evaluation on Progression-Free Survival and Overall Survival in Patients with Advanced Non–Small-Cell Lung Cancer Treated by Erlotinib in a French Prospective Cohort (ERMETIC Project—Part 2)
    Jacques L. Cadranel, Audrey Mauguen, Michèle Beau‐Faller, Gérard Zalcman, Marie‐Pierre Buisine, Virginie Westeel, Élisabeth Longchampt, Marie Wislez, Bruno P. Coudert, Catherine Daniel et al. · 2012 · Journal of Thoracic Oncology
73. Meta-analyses of gene methylation and smoking behavior in non-small cell lung cancer patients
    Tao Huang, Xiaoying Chen, Qingxiao Hong, Zaichun Deng, Hongying Ma, Yanfei Xin, Yong Fang, Huadan Ye, Rujie Wang, Cheng Zhang et al. · 2015 · Scientific Reports
74. Acquired Resistance of EGFR-Mutant Lung Adenocarcinomas to Afatinib plus Cetuximab Is Associated with Activation of mTORC1
    Pirazzoli, Valentina, Nebhan, Caroline, Song, Xiaoling, Wurtz, Anna, Walther, Zenta, Cai, Guoping, Zhao, Zhongming, Jia, Peilin, de Stanchina, Elisa, Shapiro, Erik M. et al. · 2014 · Cell Reports
75. Preclinical Modeling of KIF5B–RET Fusion Lung Adenocarcinoma
    Qingling Huang, Valentina E. Schneeberger, Noreen Luetteke, Chengliu Jin, Roha Afzal, Mikalai M. Budzevich, Rikesh J. Makanji, Gary V. Martinez, Tao Shen, Lichao Zhao et al. · 2016 · Molecular Cancer Therapeutics
76. Targeting EGFR in non-small-cell lung cancer: Lessons, experiences, strategies
    Giulia Maria Stella, Maurizio Luisetti, Simona Inghilleri, Francesca Cemmi, Roberta Scabini, Michele Zorzetto, Ernesto Pozzi · 2011 · Respiratory Medicine
77. Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
    Vijay Patil, Vanita Noronha, Amit Joshi, Anuradha Bharat Choughule, Atanu Bhattacharjee, Rajiv Kumar, Supriya Goud, Sucheta Bhagwan More, Anant Ramaswamy, Ashay Pramod Karpe et al. · 2017 · ESMO Open
78. Structure–Activity Relationship Studies Based on Quinazoline Derivatives as EGFR Kinase Inhibitors (2017–Present)
    Alexandru Șandor, Ioana A. Ionuţ, Gabriel Marc, Ilioara Oniga, Dan Tudor Eniu, Ovidiu Oniga · 2023 · Pharmaceuticals
79. Induction of apoptosis in non-small cell lung cancer by downregulation of MDM2 using pH-responsive PMPC-b-PDPA/siRNA complex nanoparticles
    Haijun Yu, Yonglong Zou, Lei Jiang, Qi Yin, Xinyu He, Lingli Chen, Zhiwen Zhang, Wangwen Gu, Yaping Li · 2013 · Biomaterials
80. PAQR3 suppresses the growth of non-small cell lung cancer cells via modulation of EGFR-mediated autophagy
    Qianqian Cao, Xue You, Lijiao Xu, Lin Wang, Yan Chen · 2019 · Autophagy
81. The combination of irreversible EGFR TKI s and SAHA induces apoptosis and autophagy‐mediated cell death to overcome acquired resistance in EGFR T 790 M ‐mutated lung cancer
    Tae‐Gul Lee, Eun‐Hui Jeong, Seo Yun Kim, Hye-Ryoun Kim, Cheol Hyeon Kim · 2014 · International Journal of Cancer
82. Suppression of TET1-Dependent DNA Demethylation Is Essential for KRAS-Mediated Transformation
    Bo-Kuan Wu, Charles Brenner · 2014 · Cell Reports
83. The role of anti-EGFR therapies in EGFR-TKI-resistant advanced non-small cell lung cancer
    Fortunato Ciardiello, Fred R. Hirsch, Robert Pirker, Enriqueta Felip, Christian Valencia, Egbert Frederik Smit · 2023 · Cancer Treatment Reviews
84. Ligand‐triggered resistance to molecular targeted drugs in lung cancer: Roles of hepatocyte growth factor and epidermal growth factor receptor ligands
    Seiji Yano, Shinji Takeuchi, Takayuki Nakagawa, Tadaaki Yamada · 2012 · Cancer Science
85. Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on Bax- and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells
    Masaru Matsumoto, Wataru Nakajima, Masahiro Seike, Akihiko Gemma, Nobuyuki Tanaka · 2016 · Biochemical and Biophysical Research Communications
86. Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer
    Arjan Gower, Yisong Wang, Giuseppe Giaccone · 2014 · Journal of Molecular Medicine
87. The prevalence of EGFR mutations in non‐small cell lung cancer in an unselected Caucasian population
    Birgit Guldhammer Skov, Estrid Vilma Solyom Høgdall, Paul Frost Clementsen, Mark Krasnik, Klaus Richter Larsen, Jens Benn Sørensen, Torsten Skov, Anders Mellemgaard · 2014 · Apmis
88. Hypoxia Promotes Resistance to EGFR Inhibition in NSCLC Cells via the Histone Demethylases, LSD1 and PLU-1
    Yuhong Lü, Yanfeng Liu, Sebastian Oeck, Peter M. Glazer · 2018 · Molecular Cancer Research
89. Structure–function analysis of oncogenic EGFR Kinase Domain Duplication reveals insights into activation and a potential approach for therapeutic targeting
    Zhenfang Du, Benjamin P. Brown, Soyeon Kim, Donna C. Ferguson, Dean C. Pavlick, Gowtham Jayakumaran, Ryma Benayed, Jean‐Nicolas Gallant, Yunkai Zhang, Yingjun Yan et al. · 2021 · Nature Communications
90. Identification of a lung adenocarcinoma cell line with CCDC 6‐ RET fusion gene and the effect of RET inhibitors in vitro and in vivo
    Makito Suzuki, Hideki Makinoshima, Shingo Matsumoto, Ayako Suzuki, Sachiyo Mimaki, Koutatsu Matsushima, Kiyotaka Yoh, Kōichi Goto, Yutaka Suzuki, Genichiro Ishii et al. · 2013 · Cancer Science
91. EGFR–TKI resistant non-small cell lung cancer (NSCLC): New developments and implications for future treatment
    Wolfram Brugger, Michael Thomas · 2012 · Lung Cancer
92. Oncogenic driver mutations in lung cancer
    Susan Yang Luo, David Chi-Leung Lam · 2013 · Translational Respiratory Medicine
93. Discovery of N -(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methyl-1,4-diazepan-1-yl)phenyl)acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR associated drug resistant mutants in NSCLC
    Yongfei Chen, Jiaxin Wu, Aoli Wang, Ziping Qi, Taoshan Jiang, Chen Cheng, Fengming Zou, Chen Hu, Wei Wang, Hong Wu et al. · 2017 · European Journal of Medicinal Chemistry
94. Platinum drugs and DNA repair mechanisms in lung cancer.
    Laura Bonanno, Adolfo Gino Favaretto, Rafael Rosell · 2014 · PubMed
95. The resistance mechanisms and treatment strategies for EGFR -mutant advanced non-small-cell lung cancer
    Wen‐Zhao Zhong, Qing Hua Zhou, Yi-Long Lung Cancer Wu · 2017 · Oncotarget
96. Synergistic inhibition of lung cancer cell invasion, tumor growth and angiogenesis using aptamer-siRNA chimeras
    Wei‐Yun Lai, Wei-Ya Wang, Yi-Chung Chang, Cheng-Ju Chang, Pan‐Chyr Yang, Konan Peck · 2014 · Biomaterials
97. Mechanisms of resistance to EGFR targeted therapies
    Gorjan Hrustanovic, Bianca J. Lee, Trever Grant Bivona · 2013 · Cancer Biology & Therapy
98. Discovery of Selective and Noncovalent Diaminopyrimidine-Based Inhibitors of Epidermal Growth Factor Receptor Containing the T790M Resistance Mutation
    Emily J. Hanan, Charles W. Eigenbrot, Marian C. Bryan, Daniel J. Burdick, Bryan K. Chan, Yuan Chen, Jennafer Dotson, Robert A. Heald, Philip S. Jackson, Hank La et al. · 2014 · Journal of Medicinal Chemistry
99. HDAC6 promotes cell proliferation and confers resistance to gefitinib in lung adenocarcinoma
    Zhihao Wang, FANG TANG, Pengchao Hu, Ying Wang, Jun Gong, Shaoxing Sun, Conghua Xie · 2016 · Oncology Reports
100. Feasibility and safety of focused ultrasound-enabled liquid biopsy in the brain of a porcine model
     Christopher Pham Pacia, Lifei Zhu, Yaoheng Yang, Yimei Yue, Arash Nazeri, H. Michael Gach, Michael Talcott, Eric C. Leuthardt, Hong Chen · 2020 · Scientific Reports